LC–MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma

    loading  Checking for direct PDF access through Ovid


Neratinib is an orally available tyrosine kinase inhibitor targeting HER2 (ERBB2) and EGFR (ERBB). It is being clinically evaluated for the treatment of breast and other solid tumors types as a single agent or in combination with other chemotherapies. In support of several phase I/II clinical trials investigating neratinib combinations, we developed and validated a novel LC–MS/MS assay for the quantification of neratinib in 100 μL of human plasma with a stable isotopic internal standard. Analytes were extracted from plasma using protein precipitation and evaporation of the resulting supernatant followed by resuspension. Chromatographic separation was achieved using an Acquity UPLC BEH Shield RP18 column and a gradient methanol-water mobile phase containing 10% ammonium acetate. An ABI 4000 mass spectrometer and electrospray positive mode ionization were used for detection. The assay was linear from 2 to 1,000 ng/mL and proved to be accurate (98.9–106.5%) and precise (<6.2%CV), and met the FDA guidance for bioanalytical method validation. This LC–MS/MS assay will be an essential tool to further define the pharmacokinetics of neratinib.

Related Topics

    loading  Loading Related Articles